- 1
- 2
Arctoris
Scientists using the Arctoris platform are able to step away from the laboratory and its time-consuming manual tasks and resume more valuable intellectual activities. Arctoris produces rich, reproducible and structured data, whilst removing the need to set-up and operate expensive laboratories - a compelling proposition for scientists of all industries. Arctoris raises the standard of research, making it faster, more cost-effective, and more reliable.
Get in contact to discuss how Arctoris can augment your research and accelerate your discovery.
Mr. Tom Fleming
Co-Founder & COOArjuna Therapeutics
The mechanism of action of our lead drug, Ag5, targets cancer cells generating high levels of Reactive Oxygen Species (ROS) via a synthetic lethality mechanism. High ROS tumours are, in general, untreatable. This group of cancers includes KRAS- and MYC-mutation driven cancers, which comprise above 30% of all cancer cases. leading to more than 1 million deaths worldwide every year. Treatment options for this group of cancers are extremely limited. We expect that our lead compound will define a new treatment paradigm across existing cancer categories. We have robust biomarkers to drive clinical development and links to world leading cancer centres in Europe and Asia.
We have a follow-on compound and a pipeline of innovative molecules addressing both cancer and non-cancerous conditions.
We are raising a series A round which will allow us to gain clinical proof of concept. Our mission is to restore hope to patients and their families.
Dr. Ross Breckenridge
CEOBIOS Health
BIOS is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals. We have leveraged recent breakthroughs in AI and Machine Learning to translate the “language” of the nervous system for the first time. Being able to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is nothing short of a game-changer, holding the key to new treatments for conditions including heart disease and diabetes.
To find out more, contact us at partnerships@bios.health.
Mr. Emil Hewage
Co-Founder, CEOCareAcross
CareAcross is a cancer-focused digital health company. Our offerings include personalized digital therapeutics via engaging online platforms. Our business services include real-world evidence, patient engagement & monitoring programs, & clinical trial recruitment.
Our clients include, among others, most of the top biopharma companies in oncology, medical devices companies, diagnostics providers, etc. Our business services are primarily based on our core assets: direct access to patients, and access to & ownership of patient data. While our focus has been in the cancer therapeutic area through our deep expertise and network, our technology is applicable to any long term or chronic condition, and enables patient engagement and improved outcomes.
Among the outcomes we can share are:
- reduced incidence of side-effects by 11%
- 5x reduction in risk of cancer malnutrition
- 65% increase in physical activity
- 68% improved patient engagement.
The approach is based on scientific evidence & guidelines: CareAcross experts process peer-reviewed journal articles on a daily basis (the company has already analysed several thousands of such articles). The applicable ones are “translated” to lay terms by experienced content writers, continuously updating the content library. The library consists of text, visuals & videos, and currently contains >500,000 words of original, patient-friendly content.
The material is selected based on each patient’s needs as entered in brief questionnaires (built entirely dynamically): advanced dynamic algorithms match each patient’s situation & needs with the right material from the content library. The level of personalisation is so deep that there are modules offering >20,000 different material combinations; the algorithms identify the most relevant for each individual patient.
Additionally, clinicians can monitor patients' progress remotely, and unobtrusively, with intuitive graphs and ongoing data collection.
The current focus areas include comorbidities, side-effects, nutrition, exercise, weight control, emotional wellbeing, and more. Furthermore, and in order to cultivate long-term engagement, CareAcross employs various methodologies including personalised newsletters, notifications, quantified-self techniques with intuitive scores & graphs, and others.
As a result, CareAcross delivers long-term, engaging, personalised coaching services to cancer patients, via material which is always available to them.
The approach does not aim to replace patients’ healthcare teams and clinicians, but to support patients in the majority of their time (95% on average) which they spend outside the clinic.
Our Patient Operations are active in several countries and continents.
Our Chief Medical Officer is a medical oncologist, and has been a president of the European Society for Medical Oncology (ESMO), among others. Our Chief Executive Officer is a member of the Assembly of the European Commission's Cancer Mission.
We have been awarded 3 grants by the European Commission on Big Data and Artificial Intelligence in Cancer enabling international collaborations with established centers of excellence.
We have been profitable in the last 4 accounting periods.
Thanos Kosmidis
CEOCharnwood Molecular Ltd
Dr. Aji Thomas
Business Development ExecutiveConnexin Therapeutics Ltd.
Connexin Therapeutics raised ~£150,000 in Seed financing in early 2019. These funds are being used to synthesize and test novel small molecules in animal models of glaucoma. Selected results from these studies are presented in this document. These compounds are based on a molecule which has already demonstrated efficacy in mouse models of glaucoma. Thus, these data supplement and extend the work already published.
We are currently raising ~£2,000,000 to expand our synthesis and optimize our lead compounds. After ~8-10 quarters of work we anticipate having a library of patentable compounds which are highly selective for our target, backed by cell and animal data. We may also have a second compound which inhibits a different retinal target for a different set of conditions. Future financing rounds will take one or both leads into formulation development, safety studies, and clinical trials, while also fueling our expansion into other indications with this same mechanism of action.
Carlos Velez
CEOElasmogen Ltd
We are currently looking for partners for our existing assets and also companies who would like to access our powerful, patent protected soloMER platform to develop new products.